S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

Tilray Stock Forecast, Price & News

-0.20 (-5.49%)
(As of 06/28/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
17.77 million shs
Average Volume
29.37 million shs
Market Capitalization
$1.71 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Stock Forecast (MarketRank)

Overall MarketRank

1.67 out of 5 stars

Consumer Staples Sector

139th out of 195 stocks

Medicinals & Botanicals Industry

10th out of 23 stocks

Analyst Opinion: 3.1Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
Tilray logo

About Tilray (NASDAQ:TLRY)

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

TLRY Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
$-367.42 million
Pretax Margin


Sales & Book Value

Annual Sales
$513.09 million
Book Value
$9.98 per share


Free Float
Market Cap
$1.71 billion

Tilray Frequently Asked Questions

Should I buy or sell Tilray stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Tilray stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View analyst ratings for Tilray
or view top-rated stocks.

What is Tilray's stock price forecast for 2022?

11 brokerages have issued 12 month target prices for Tilray's stock. Their TLRY stock forecasts range from $3.00 to $12.00. On average, they predict Tilray's share price to reach $7.68 in the next year. This suggests a possible upside of 123.1% from the stock's current price.
View analysts' price targets for Tilray
or view top-rated stocks among Wall Street analysts.

How has Tilray's stock performed in 2022?

Tilray's stock was trading at $7.03 on January 1st, 2022. Since then, TLRY stock has decreased by 51.1% and is now trading at $3.44.
View the best growth stocks for 2022 here

When is Tilray's next earnings date?

Tilray is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Tilray

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) issued its quarterly earnings results on Wednesday, April, 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.12. The company earned $151.90 million during the quarter, compared to the consensus estimate of $156.64 million. Tilray had a negative trailing twelve-month return on equity of 0.78% and a net margin of 6.80%. The company's quarterly revenue was up 22.6% on a year-over-year basis.
View Tilray's earnings history

Who are Tilray's key executives?

Tilray's management team includes the following people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray CEO Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among Tilray's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (0.00%), Vanguard Group Inc. (0.41%), Group One Trading L.P. (0.00%), IMC Chicago LLC (0.00%), Sculptor Capital LP (0.00%) and Sculptor Capital LP (0.00%). Company insiders that own Tilray stock include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends for Tilray

Which major investors are selling Tilray stock?

TLRY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Wolverine Asset Management LLC, Twin Tree Management LP, Group One Trading L.P., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, TD Asset Management Inc., and UBS Group AG. Company insiders that have sold Tilray company stock in the last two years include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood, and Michael Auerbach.
View insider buying and selling activity for Tilray
or view top insider-selling stocks.

Which major investors are buying Tilray stock?

TLRY stock was purchased by a variety of institutional investors in the last quarter, including IMC Chicago LLC, Jane Street Group LLC, Sculptor Capital LP, Sculptor Capital LP, Prentice Capital Management LP, Bank of Montreal Can, Greenwich Wealth Management LLC, and Hall Private Wealth Advisors.
View insider buying and selling activity for Tilray
or or view top insider-buying stocks.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $3.44.

How much money does Tilray make?

Tilray (NASDAQ:TLRY) has a market capitalization of $1.71 billion and generates $513.09 million in revenue each year. The company earns $-367.42 million in net income (profit) each year or $0.19 on an earnings per share basis.

How many employees does Tilray have?

Tilray employs 2,100 workers across the globe.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for Tilray is www.tilray.com. The company can be reached via phone at 206-432-9325.

This page (NASDAQ:TLRY) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.